Literature DB >> 1313595

Vasoactive intestinal peptide: autocrine growth factor in neuroblastoma.

M S O'Dorisio1, D J Fleshman, S J Qualman, T M O'Dorisio.   

Abstract

Neuroblastoma is the most common solid tumor of children less than 5 years of age; yet the biology of this tumor is poorly understood. Neuroblastoma tumors are derived from neural crest precursors; they synthesize both adrenergic and peptidergic neurotransmitters. This study determined VIP receptor expression in primary neuroblastoma tumors prior to chemotherapy. The VIP receptor was expressed in 12 of 15 neuroblastoma tumors as determined by direct binding studies (KD = 1.3-12.4 nM) and VIP-mediated stimulation of adenylate cyclase. The VIP stimulation index for adenylate cyclase in the primary tumor was inversely correlated with the VIP content of the tumor, suggesting that VIP regulates its own receptor expression. Similar observations were made in vitro by comparison of two human neuroblastoma cell lines, IMR32 and SKNSH. Both cell lines were demonstrated to express specific, high affinity VIP receptors (KD = 4 nM and 2.5 nM for IMR32 and SKNSH, respectively). IMR32 cells contained very low levels of VIP (0.6 pg VIP/10(6) cells). Exogenous VIP stimulated adenylate cyclase 22-fold over basal activity and VIP inhibited proliferation of IMR32 cells by 49% in 6-day cultures. On the other hand, SKNSH cells synthesized high levels of VIP (6.3 pg/10(6) cells), metabolized VIP rapidly and demonstrated a low level of VIP-mediated stimulation of adenylate cyclase; their proliferation rate was minimally inhibited by exogenous VIP. These observations help validate the hypothesis that VIP serves as an autocrine growth factor in neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313595     DOI: 10.1016/0167-0115(92)90616-3

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  8 in total

1.  (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.

Authors:  Terry W Moody; Robert T Jensen; Mati Fridkin; Illana Gozes
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

Review 2.  VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment.

Authors:  J M Muller; V Lelievre; L Becq-Giraudon; A C Meunier
Journal:  Mol Neurobiol       Date:  1995 Apr-Jun       Impact factor: 5.590

Review 3.  Nanoparticle ligand presentation for targeting solid tumors.

Authors:  Jason T Duskey; Kevin G Rice
Journal:  AAPS PharmSciTech       Date:  2014-06-14       Impact factor: 3.246

4.  Expression and fine mapping of murine vasoactive intestinal peptide receptor 1.

Authors:  B Karacay; M S O'Dorisio; K Kasow; C Hollenback; R Krahe
Journal:  J Mol Neurosci       Date:  2001-12       Impact factor: 3.444

Review 5.  Role of gastrointestinal hormones in neuroblastoma.

Authors:  W Clay Gustafson; Brittany B De Berry; B Mark Evers; Dai H Chung
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

6.  Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro.

Authors:  Christine Dufes; Céline Alleaume; Alicia Montoni; Jean-Christophe Olivier; Jean-Marc Muller
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

7.  Vasoactive intestinal peptide enhances its own expression in sympathetic neurons after injury.

Authors:  R P Mohney; R E Zigmond
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

8.  A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells.

Authors:  A Sharma; J Walters; Y Gozes; M Fridkin; D Brenneman; I Gozes; T W Moody
Journal:  J Mol Neurosci       Date:  2001-12       Impact factor: 3.444

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.